News & Updates
Filter by Specialty:
Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy
First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.
Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy
06 Nov 2025
Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).
Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
05 Nov 2025
SGLT-2i lowers autoimmune rheumatic disease risk in T2D
The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, results in a reduced risk of autoimmune rheumatic disease among adults with type 2 diabetes (T2D), reports a recent study.
